Related Experiment Video

Updated: May 2, 2026

Identification of Kinase-substrate Pairs Using High Throughput Screening
11:13

Identification of Kinase-substrate Pairs Using High Throughput Screening

Published on: August 29, 2015

7.8K

Activation pathway of Src kinase reveals intermediate states as targets for drug design

Diwakar Shukla1, Yilin Meng2, Benoît Roux3

  • 11] Department of Chemistry, Stanford University, Stanford, California 94305, USA [2] SIMBIOS NIH Center for biomedical computation, Stanford University, Stanford, California 94305, USA.

Nature Communications
|March 4, 2014
PubMed

Insights

Understanding Src kinase activation is key to cancer therapy. This study maps kinase conformational changes, revealing new drug targets for cancer treatment.

Area of Science:

  • Biophysics
  • Computational Biology
  • Cancer Research

Background:

  • Unregulated Src kinase activation drives cancer by promoting aberrant cell signaling, growth, and differentiation.
  • A deep mechanistic understanding of kinase activation dynamics is crucial for developing targeted cancer therapies.
  • Simulating these large-scale conformational changes in silico is computationally challenging due to long activation timescales.

Purpose of the Study:

  • To computationally map the conformational landscape of c-src tyrosine kinase activation.
  • To elucidate the thermodynamics and kinetics governing kinase activation.
  • To identify key structural intermediates and potential allosteric drug-binding sites.

Main Methods:

  • Coupling transition pathway techniques with Markov state model-based massively distributed simulations.
  • Utilizing atomistic molecular dynamics simulations to model kinase conformational transitions.
  • Analyzing the conformational landscape of c-src tyrosine kinase.

Main Results:

  • The study provides the first computational insights into the thermodynamics and kinetics of c-src tyrosine kinase activation.
  • Key structural intermediates involved in the kinase activation process were identified.
  • A novel allosteric site in an intermediate state of c-src was predicted, offering potential for drug design.

Conclusions:

  • This computational approach successfully maps the complex conformational landscape of kinase activation.
  • The identified intermediates and novel allosteric site represent promising avenues for developing new kinase-targeted cancer drugs.
  • Mechanistic insights into Src kinase activation can significantly aid in the design of more effective cancer therapeutics.

More Related Videos

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.1K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
15.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K